Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

sen is

currently in phase 3 development for patients with homozygous familial

hypercholesterolemia, and a U.S. marketing application for this

indication is anticipated in 2009. The product offers an innovative

approach to addressing a real, unmet medical need, and Genzyme believes

it could prove to be the most effective lipid-lowering agent for high

risk cardiovascular disease patients for whom conventional therapies

are not sufficient. The product may potentially provide significant

benefit over the standard of care and targets a well-defined and

severely ill patient population.

Alemtuzumab for multiple sclerosis

-- Genzyme is enrolling patients in two phase 3 trials examining the

safety and efficacy of alemtuzumab for the treatment of multiple

sclerosis. One study includes previously untreated patients and one

involves patients whose disease remains active following treatment with

an approved therapy. Alemtuzumab's effect in treating MS, observed in

clinical studies, exceeds that of any currently marketed products and

any products in development. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is investing in the development of an innovative, next-

generation product for the treatment of Gaucher disease. The company

has completed enrollment in a phase 2 trial of the small molecule

Genz-112638, a novel oral therapy that could provide an additional

treatment option for physicians and patients. Initial results for the

first group
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... MA -- Vasectomy was associated with a small increased ... advanced or lethal prostate cancer according to a new ... researchers found that the association remained even among men ... of lethal cancer cannot be explained by diagnostic bias. ... date to look at the link between vasectomy and ...
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... that fecal transplantation is effective and safe for treating ... the result of a study led by Colleen Kelly, ... Medicine at The Women,s Medicine Collaborative. The study and ... print in the American Journal of Gastroenterology . ... , has increased to epidemic proportions over the past ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
... effective, long-term treatment for trigeminal neuralgia: a painful condition ... sclerosis (MS). Radiation is noninvasive and has less negative ... follow-up in a study of its kind presented October ... American Society for Radiation Oncology (ASTRO). Multiple ...
... HealthDay Reporter , MONDAY, Oct. 25 (HealthDay News) -- ... infants will start sleeping through the night between 2 and ... longer, however, is for the baby,s eight hours of slumber ... study. "The most rapid changes in infant sleep were ...
... cancer drug could be produced cheaply and sustainably using stem ... isolated and grown stem cells from a yew tree whose ... The development could enable the compound to be produced on ... Scientists and engineers behind the development say the ...
... reason many smokers struggle to quit. According to new ... history of anxiety disorders are less likely to quit ... Center for Tobacco Research and Intervention (UW-CTRI), offered free ... , While overall quit rates for the study were ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, Oct. ... with more than half of the segments in the heart,s main ... a new study shows. The good news? Other parts ... within three months or fewer after the run, the researchers found. ...
... HealthDay Reporter , SUNDAY, Oct. 24 (HealthDay News) -- Concussions ... Just last week, the National Football League announced it would ... result in head injuries. Now, a new 12-year study ... been sidelined significantly longer after concussions than they were in ...
Cached Medicine News:Health News:Radiation therapy improves painful condition associated with multiple sclerosis 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:Plant stem cells could be fruitful source of low-cost cancer drug 2Health News:Common anxiety disorders make it tougher to quit cigarettes 2Health News:Marathons Affect Heart, but Runners Bounce Back 2Health News:Marathons Affect Heart, but Runners Bounce Back 3Health News:NFL Players With Concussions Sidelined Longer: Study 2Health News:NFL Players With Concussions Sidelined Longer: Study 3
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool....
High temperature loop tip cautery....
Low temp, micro fine tip, patented Aaron RAM cauteries....
6 mm, 45 degree upwards, detachable....
Medicine Products: